In fact, this also limits the opportunity of prevention for BRCA1/2-mutant breast cancer and other tumors such as ovarian cancer, due to the cost effectiveness for extending to population-based sequencing (sequencing costs not offset by healthcare benefits of preventing future malignancies) (Gourley, 2019) and limitations of BRCA gene mutation detection. The gene discussed is BRCA1; the disease is breast cancer.